Tagged with R&D

Mexico Arturo Rodríguez Jacob, CEO at Infinite Clinical Research (ICR) and president of the national association of CROs (ACROM), explains what make Mexico the regional clinical research hub and showcases how ICR is developing clinical studies for allopathic, biotech, medtech, and herbal medicine companies. Only 15 years ago, the Mexican clinical…

Italy Prof. Luca G. Guidotti discusses the esteemed positioning of San Raffaele within the global scientific community, their core mission of translational medicine and the challenges Italy faces today with the development of young scientific talent and the bridging of the public-private gap. Prof. Guidotti, could you begin by describing the…

Italy The division of neuroscience at the San Raffaele Scientific Institute is one of the best worldwide performers in academic research. Division director Professor Gianvito Martino discusses the institute’s unique operative model, national limitations, and the future of the neuroscience field as an investment opportunity. Prof. Martino, to start off, the…

Italy Professor Angelo Corti, Director of the Experimental Oncology division of the SRSI, discusses approaches to oncology research and the institute´s significant contribution to the field in Italy. What is the philosophy of the SRSI’s oncology division towards oncology research? The development of new strategies to improve cancer prevention, detection and…

Italy Dr. Paola Pozzi, the head of the Office of Biotechnology Transfer at the San Raffaele Scientific Institute, discusses the crucial role the OBT occupies as a link between the industry and early-stage research at the institute, as well as her views on the changing culture surrounding the commercialization of research…

Switzerland Recognized as one of the ten most innovative companies in the world, Hamilton has a regional HQ, strategic R&D and manufacturing operations tucked high away in the scenic Swiss Alps. Andreas Wieland, CEO of Hamilton’s Swiss businesses, discusses the company’s approach to innovation and the factors that have helped Switzerland…

Taiwan Mike Exton, Managing Director at Novartis Taiwan, describes the affiliate’s plans to increase collaboration with the government in order to provide Taiwanese patients with a greater access to innovative, life-changing products, while highlighting Novartis’ world-class innovation in many critical therapeutic areas, such as heart failure, as well as the skilled…

Taiwan Yung Fa Chen, ScinoPharm’s President and CEO, documents his strategy to drive the Taiwan-based global success story to new heights, having established itself as an indisputable leader in the API field, providing its international partners with complex, difficult-to-make products. Yung Fa Chen notably explains how he wants to further leverage…

Greece In a landscape starved for innovative medicine, clinical trials stand as a beacon of hope for critical care patients in need of the latest high-value treatments. Pioneering the development of a thriving CRO environment is Andreas Moschos, founder of NextCRO, who fully embodies the forward-thinking values invoked by the company’s…

Taiwan George Lee and Tzu-Ming Pan introduce SunWay Biotech’s groundbreaking red yeast rice extract, ANKASCIN® 568-R, which has been recognized as a New Dietary Ingredient by the US FDA. SunWay Biotech is now bringing this unique product onto the global stage and are considering developing a pharmaceutical product based on the…

Mexico Paulo de Resende, CEO of Laboratorios Grin-Lupin in Mexico, describes the current state of the Mexican pharmaceutical market and explains how the acquisition of Laboratorios Grin will help increase Lupin’s footprint in Latin America by bringing more expertise and R&D resources. Could you please introduce yourself to our international audience…

Taiwan Tse Wen Chang, internationally recognized as one of the greatest contributors to the biotech field, and founder, CEO, and president of Immunwork, provides insights into the company’s ground-breaking T-E™ pharmaceuticals, which combine both targeting (T) and effector (E) moieties to form a new class of innovative drugs displaying significantly enhanced…